We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

International Chronic Myeloid Leukemia Pediatric Study (ICMLPed)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01281735
Recruitment Status : Recruiting
First Posted : January 24, 2011
Last Update Posted : October 11, 2017
Sponsor:
Collaborators:
Institut National de la Santé Et de la Recherche Médicale, France
University of Milano Bicocca
University Medical Center Groningen
University Hospital of Liege
Imperial College London
University Hospital Dresden
International BFM Study Group
Information provided by (Responsible Party):
Poitiers University Hospital

Brief Summary:
The purpose of the study is to describe and characterize CML in a large pediatric cohort of patients.

Condition or disease
Chronic Myeloid Leukemia

  Show Detailed Description

Study Type : Observational
Estimated Enrollment : 750 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: INTERNATIONAL STUDY of Chronic Myeloid Leukaemia (CML) Treatment and Outcomes in Children and Adolescents
Study Start Date : January 2011
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients less than 18 years of age with newly diagnosed Philadelphia positive and/or bcr-abl positive CML are eligible whatever the phase of the disease, the type of treatment and the enrollment or not in a clinical study.
Criteria

Inclusion Criteria:

  • patients less than 18 years of age
  • diagnosed Philadelphia positive and/or BCR-ABL positive Chronic Myeloid Leukemia (CML) all phases

Exclusion Criteria:

  • patients more than 18 years of age at diagnosis of CML

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01281735


Contacts
Contact: Frederic MILLOT, MD +33 (0)5 49 44 30 78 f.millot@chu-poitiers.fr

  Show 20 Study Locations
Sponsors and Collaborators
Poitiers University Hospital
Institut National de la Santé Et de la Recherche Médicale, France
University of Milano Bicocca
University Medical Center Groningen
University Hospital of Liege
Imperial College London
University Hospital Dresden
International BFM Study Group
Investigators
Principal Investigator: Frederic MILLOT, MD Poitiers University Hospital

Responsible Party: Poitiers University Hospital
ClinicalTrials.gov Identifier: NCT01281735     History of Changes
Other Study ID Numbers: CIC09-33
2010-023359-27 ( EudraCT Number )
First Posted: January 24, 2011    Key Record Dates
Last Update Posted: October 11, 2017
Last Verified: October 2017

Keywords provided by Poitiers University Hospital:
treatment outcome
side effects
Protein Kinase Inhibitors
pediatrics

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases